The Financial Times seems to suggest that the work of the Medicines Patent Pool could lead to more inappropriate HIV medicines when it quotes Johnson & Johnson`s Paul Stoffels as saying the Pool could trigger "mixing and matching" of medicines leading to resistance to innovative HIV drugs ("J&J censured for block on HIV drug patents," 23 December 2011, available here: http://www.ft.com/intl/cms/s/0/d6ca3afa-2cbf-11e1-b485-00144feabdc0.html ).
This is a disturbing and untrue statement. Ensuring that the right HIV medicines are available ? in particular "3-in-one pills", or Fixed-Dose Combinations ? at low costs is at the core of the Pool`s mission. In order to achieve this goal, the Pool is working closely with HIV treatment experts, including WHO and UNAIDS, to ensure that its work meets the needs of people living with HIV and the doctors who treat them. Examples of this are:
